Remove Immunity Remove Immunization Remove Packaging
article thumbnail

STAT+: The race to build better CRISPR delivery vehicles is heating up

STAT

In the pipeline are treatments that attempt to accomplish this by borrowing stealthing technologies from other fields, like gene therapy’s viral vector workhorse, AAV , or the lipid nanoparticles that coat RNA-interfering drugs and mRNA vaccines.

Packaging 357
article thumbnail

STAT+: Pharmalittle: Weight-loss drug ads pose new oversight challenge; will the new Bayer CEO split the company?

STAT

They may involve infusions of a gene packaged inside the shell of a virus, which can lead to potential immune complications and can require close monitoring of patients. Promising therapies for some diseases are administered through lumbar punctures, which are not a routine part of a doctor’s daily practice.

Packaging 245
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA declines Eli Lilly’s bowel disease drug over manufacturing issues

Pharmafile

However, concerns weren’t expressed over the clinical data package, safety or label for the medicine. Mirikizumab was hoped to become a new drug treatment for ulcerative colitis (UC), a condition where abnormal reactions in the immune system cause inflammation in the inner lining of the colon. read more

Packaging 119
article thumbnail

CanSinoBIO developed a highly effective COVID vaccine with an inhalant version

pharmaphorum

It then elicits an immune response against that spike protein. Morgon says CanSinoBIO produced an inhalant version of Convidencia because an immune response called mucosal immunity is triggered in addition to the circulating antibodies and the T cell response. There’s no additional replication in the person.

Vaccines 138
article thumbnail

New antibody could be promising cancer treatment

World Pharma News

Researchers have developed a unique type of antibody that both targets and delivers a drug package via the antibody itself, while simultaneously activating the immune system ("3-in-1 design") for personalised immunotherapy treatments. The study has been published in Nature Communications.

article thumbnail

The next generation of immunotherapy? Innate Pharma targets NK cells

pharmaphorum

Founded in 1999, Marseille-based company Innate Pharma is on a mission to develop immunotherapies that take advantage of the body’s innate immune system. The cytokine release prompts T-cells so they can translate that first innate immune response into a long-lasting adaptive immune response. About the interviewee.

Immunity 122
article thumbnail

Oncolytic viruses: past and present

European Pharmaceutical Review

This strategy has failed to gain a foothold in the past as the patient’s immune system interferes, destroying the unprotected oncolytic viruses. 7 Studies also sought to modify oncolytic viruses with additional genes that more efficiently recruit the patient’s immune system to target tumour cells. suppressing activity.

Immunity 111